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Abstract Background: Adverse reaction to metal debris is
a relatively recently described and often a silent complica-
tion of metal-on-metal (MOM) total hip replacements
(THR). The Norfolk & Norwich University Hospital has
been performing metal artefact reduction (MARS) MRI for
8 years in a variety of different types of MOM THR.
Questions/purposes: The aims of this review are to describe
the experience of using MARS MRI in Norwich and to
compare our experience with that published by other groups.
Methods: A MEDLINE keyword search was performed for
studies including MRI in MOM THR. Relevant publications
were reviewed and compared with published data from the
Norfolk & Norwich University Hospital. The similarities
and differences between these data were compared and
possible explanations for these discussed. Results: MARS
MRI appears to be the most useful tool for diagnosing,
staging and monitoring adverse reactions to metal debris
(ARMD). There appears to be no clinically useful associa-
tion between clinical and serological markers of disease and
the severity of MR findings. Although severe early ARMD
is associated with significant morbidity, mild disease is often
stable for years. If patients with normal initial MR
examinations develop ARMD, this usually occurs 7 years.
A 1-year interval between MRI examinations is reasonable
in asymptomatic patients. Conclusions: There is a general
international consensus that ARMD is prevalent in symptom-
atic and asymptomatic patients with MOM THR and that
while appearances vary with the type of prosthesis, there are
characteristic features that make MARS MRI essential for
diagnosis, staging and surveillance of the disease.
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Introduction
Orthopaedic surgery in Norwich first gained recognition
with Tommy Brittain who pioneered extra-articular arthrod-
esis for arthritis [7], but it was his one-time registrar Ken
McKee who set the scene for the later experience in imaging
of metal-on-metal (MOM) arthroplasties. Ken McKee had
also worked for Philip Wiles who in 1938 performed what is
widely recognized as the first documented total hip replace-
ment (THR) at the Middlesex Hospital, in London, using
stainless steel acetabular and femoral prostheses [11].
McKee was hooked. While his medical career was
interrupted by active service with the Royal Army Medical
Corp during World War II, he continued to think about the
possibilities of hip arthroplasty writing in 1940 that “If one
could replace the bearing of a motor car then it must be
possible in human joints” (personal communication: Mr
Hugh Phillips, Consultant Surgeon, Norwich, 2002).
After the end of the war, McKee was appointed as a
consultant at the Norfolk & Norwich University Hospital. At
this time, the wisdom of his peers was that arthrodesis was
the best treatment for the arthritic hip and that artificial joints
were doomed to fail. Despite the prevailing sentiment,
McKee designed and improved a series of MOM total hip
replacements culminating in 1965, with the assistance of
John Watson-Farrar, in the McKee–Farrar: a cobalt–chromi-
um–molybdenum alloy MOM THR with a studded “sput-
nik” acetabular cup and a cemented collared femoral
prosthesis [3, 5, 11] (Fig. 1a).
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The McKee–Farrar became the first widely implanted
total hip replacement, but it was not without its problems.
Early- to medium-term failure was caused by mechanical
loosening with two thirds of these hip replacements demon-
strating radiographic loosening followed by a revision rate
of 10% to 17% by 10 years [3, 11]. The cause of this
relatively high rate of early aseptic loosening has been
attributed to both surgical technique and biomechanical
problems of the bearing itself, which were felt to reflect
the limits of the engineering techniques of the time prior to
1971. The McKee–Farrar was an equatorial loaded bearing
as opposed to later polar bearing designs, and this was
considered to be a major cause of loosening in the earlier
implants due to high friction. Elevated serum metal ion
levels were found in patients with MOM prostheses, and
the concern that this may be associated with carcinogenicity
contributed to the decline in popularity of the McKee–Farrar
and the coming of age of Charnley’s metal on polyethylene
(MOP) “low friction arthroplasty” in the early 1970s [23]
despite the fact that the intermediate- and long-term results
of the McKee–Farrar and Charnley were comparable [3, 24].
After the predominance of MOP systems in the late
1970s and 1980s, aseptic loosening caused by osteolysis
from polyethylene wear debris became an increasingly com-
mon problem. In an attempt to find an alternative, manufac-
turers revisited the MOM concept. Long-term data revealed
that when MOM implants were successful, outcomes were
excellent with significantly lower wear (two orders of mag-
nitude lower) of the metal bearing components than MOP
arthroplasty [2, 24, 39] with reports of MOM bearings
lasting for over two decades [2]. The expectation was that
with improved tolerances resulting from new machining
techniques, the short- to medium-term failures of the
McKee–Farrar could be addressed, and so by 1988, MOM
hip replacement systems had been reintroduced and by 1997
MOM arthroplasty had returned to Norwich.
This review describes the experience of imaging these
modern MOM THR in Norwich and compares our experi-
ence with that of other groups. In particular, this review will
focus on four specific questions. These are: (1) What are the
MR appearances of the normal post-operative hip? (2) What
are the characteristic MR features of ARMD? (3) How do
these features correlate with other biomarkers of disease? (4)
What is the prognosis for patients with mild disease or
normal MRI early in their post-operative course?
Method and Materials
Search Strategy
On the 14th July 2013, a word search of MEDLINE was
performed using the terms “metal-on-metal” AND “MRI”.
This search produced 51 articles. Case reports, reviews,
letters and lecture notes (12) were excluded along with
publications that did not specifically report analysis of ra-
diological findings in their results (11), any publications
from Norwich (6) and a single paper not in English. This
left 21 original scientific articles from institutions other than
our own. The comparison of these papers with the results
from Norwich forms the basis of this review.
Fig. 1. Plain radiographs illustrating a McKee–Farrar (a), a first-generation MOM THR, and a modern MOM THR, a hybrid Ultima TPS (b) with
minimal resorption of the medial calcar (c) as the only sign in a patient with extensive ARMD.
Fig. 2. Intra-operative photograph demonstrating severe ARMD with
a large head metal-on-metal THR. Extensive soft tissue destruction is
associated with complete detachment of the abductors from the greater
trochanter which allow visualization of the prosthesis.
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Types of MOM THR
Experience of imaging failing MOM arthroplasties in Nor-
wich includes several different types including total hybrid,
total uncemented, large and small bearing and resurfacing
arthroplasties.
Hybrid Total Hip Arthroplasty: Small Bearing
Between 1997 and 2004, 545 patients underwent 652 total
hip replacements using an Ultima hybrid (then Johnson and
Johnson Professional, now DePuy International Ltd, UK)
MOM THR, initially as part of a multicentre clinical inves-
tigation into the safety and efficacy of the Ultima MOM
THR. By January 2008, nearly 14% had been revised. Pain
was the most common indication for revision (49%) follow-
ed by peri-prosthetic fractures (19%) [9]. At revision surger-
y, the findings included peri-prosthetic cavities containing
milky fluid under pressure, soft tissue necrosis, tendon avul-
sion and osteonecrosis of the proximal femur (Fig. 2). His-
tology demonstrated extensive necrosis, fibrosis and dense
peri-vascular lymphocytic infiltrates in keeping with aseptic
lymphocytic vasculitis-associated lesions (ALVAL) [10, 12,
13]. Various terms have been used to describe this disease.
ALVAL is probably best restricted to histopathological find-
ings whereas adverse reactions to metal debris (ARMD) is
more suitable to the range of bone and soft tissue changes
seen at operation and on MRI.
Uncemented Large Bearing: Total and Resurfacing
Between 2005 and 2008, 79 ASR-XL hip arthroplasties
were performed in 68 patients (17 resurfacing and 62 total).
Cobalt-chrome (CoCr) acetabular components and large
bearing CoCr femoral heads were used in all cases, with
the addition of a Corail titanium femoral prosthesis in the
total hip arthroplasties [14]. Following the experience with
the Ultima TPS hybrid THR and following an index case
that was revised early for pain and soft tissue abnormalities
on MRI, the whole cohort of these patients underwent an-
nual clinical assessment and self-assessment questionnaires
including annual radiographs and MRI. There was a high
early revision rate of 11% at 40 months for the ASR cohort
[14] which was comparable with published results from
other groups [15–17].
From 2001 to 2007, 463 Birmingham hip resurfacing
arthroplasties (BHR) were performed in Norwich and a local
district general hospital. The revision rate at 5 years was 3.1%
with risk factors identified as female gender, high acetabular
inclination, obesity and small femoral components [18].
The BHR is the most successful MOM prosthesis in the
National Joint Registry of England & Wales [19], with a
revision rate of 5.09% at 7 years, but even this compares
poorly with a cemented Exeter MOP THR at 1.32%. The
BHR is now reserved, by most British hip surgeons, for
younger men with large femoral heads, who appear to have
the lowest risk of revision.
Table 1 The Norwich MAR MR protocol at 1.5 T (Siemens Sympho-
ny, Erlangen, Germany)
T1 T2 T2 T1 STIR
Plane Axial Sag Axial Cor Cor
Field of view (cm) 34×27 34×34 34×34 34×34 34×34
Base resolution 384 448 384 320 320
TE (ms) 9.7 64 69 7.3 38.0
TR (ms) 574 3,040 5,040 815 3,000
Slice thickness (mm) 6.0 5.0 6.0 5.0 5.0
Interslice gap (mm) 1.5 1.0 1.0 1.0 1.0
Receiver bandwidth (Hz/pixel) 501 507 501 504 504
Phase encoding direction A>P H>F R>L F>H F>H
A anterior, P posterior, R right, L left, F foot, H head
Fig. 3. Graph demonstrating the reduction in metal artefact with increasing receiver bandwidth for different matrix sizes. For any matrix size, a
receiver bandwidth of 600 Hz/pixel or more produces 90% of the achievable reduction in artefact.
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Imaging Protocols
Radiography
One of the key radiological findings in ARMD is that conven-
tional radiographs are usually normal. The most commonly
recognized radiographic finding is resorption of the medial
calcar, which is often subtle and does not reflect the sometimes
extensive soft tissue changes [26, 47] (Fig. 1b, c). Interestingly
some of the features that are now widely recognized on MRI
were first described using conventional arthrography in 1975
although at the time ALVAL and ARMD were not recognized
as a unique disease process [1].
CT
Our experience of using CT for the detection of ARMD is
limited to those patients with absolute contraindications to
MR although some institutions appear to use it routinely
with success [6]. Others have used it for 3D measurements
of the position of the prosthesis in which there appears to be
no difference between symptomatic and asymptomatic pa-
tients supporting the hypothesis that patient-specific factors
are more influential [16, 17, 29].
MRI
The MR protocol in Norwich has evolved since MR of THR
started in 2005. Machines have changed offering stronger
gradients, but our basic protocol has remained the same for
most of this time and includes fast spin echo and short tau
inversion recovery (STIR) sequences in three planes with
alternating phase and frequency encoding directions used to
“steer” artefact away from tissues of interest (Table 1).
The matrix sizes and receiver bandwidth were deter-
mined following phantom studies. Both can be used to
reduce artefact, but each comes with a penalty: increased
acquisition times with smaller voxel sizes and reduction of
signal-to-noise ratios with increasing receiver bandwidths.
In fact the reduction in SNR associated with increasing
bandwidth does not significantly adversely affect the diag-
nostic quality of the images and so increasing the receiver
bandwidth has been our primary tool for metal artefact
reduction. The matrix is determined by anatomical resolu-
tion requirements alone [43] (Fig. 3).
Our preferred method of fat suppression is to use STIR
imaging. STIR images are limited by signal, and as a result,
some authors advocate using a two-point Dixon technique
producing separate fat and water sensitive images [8]. How-
ever, in our experience, using comparable imaging parameters,
the near metal artefact is worse with two-point Dixon-based
techniques than with STIR (Fig. 4).
Not all radiologists use T2W sequences as part of a MARS
MRI protocol. The longer echo times are more susceptible to
dephasing, but we find this useful to identify microscopic
metal debris which is not always visible on very short echo
T1W or PD sequences.
Fig. 4. Fat suppression using coronal STIR (a) and two-point Dixon IDEAL (b) sequences demonstrating optimal control of susceptibility
artefact with STIR.
Fig. 5. Axial T1W (a) and T2W (b) fast spin echo in a patient with bilateral MOM THR demonstrating the typical appearance of ARMD in the
Ultima TPS hip with intermediate signal on T1W and fluid signal enclosed in a thick ragged very low signal pseudocapsule on T2W (arrow).
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This protocol comprises basic modifications to standard
spin echo and STIR sequences. There are a number of more
advanced techniques for metal artefact reduction which in-
clude view angle tilting and multi-spectral imaging tech-
niques such as MAVRIC and SEMAC, but we have not
used these as part of our routine practice [15, 21, 40]
Results
MRI of the Normal THR
Early work optimizing MR for imaging concentrated on im-
aging the predominantly soft tissue complications of THR [35,
36, 45]. Soon after we started to MR image large numbers of
patients with MOM THR, we realized that the normal post-
operative MR appearances for THR were not clearly defined.
This meant that some abnormalities such as muscle wasting
might be attributable to the pre-existing disease or the opera-
tion. The presence of gluteus minimus atrophy and fluid
collections around the greater trochanter had been previously
demonstrated on MR imaging of asymptomatic patients fol-
lowing lateral transgluteal arthroplasty [34].
In order to define the normal spectrum of post-operative
MRI findings, a cross-sectional observational study of 22
asymptomatic hips after MOP (n=10) and MOM (n=12)
arthroplasty was performed. This revealed that short external
rotator muscle atrophy was a standard finding in THRs
performed using a posterior approach, even when the tendon
was reattached, which it was in all these cases. It was also
apparent that small simple thin-walled periprosthetic fluid
collections were commonly found in the surgical bed and
presumably represented post-operative seromas [30]. Simi-
lar results have been described by other authors [22].
One of the original features described as part of the
spectrum of findings in ARMD on MRI was bone marrow
oedema on the STIR sequences, but it became apparent that
the inter-observer reliability for this feature was poor and it
was dropped from routine clinical reporting practices.
MRI of ARMD
A case report of two patients with soft tissuemasses associated
with MOM THR had been published shortly in 2007; howev-
er, ALVAL had not been identified as the histological diagno-
sis although the description of histological features of a
hypersensitivity reaction that would be consistent with
ALVAL [14]. MAR MRI of the first 20 MOM THRs in 19
patients from Norwich demonstrated soft tissues changes of
ALVAL that had not previously been systematically described
on MRI [41]. The typical MR appearance in the Norwich
Ultima TPS THR was one of periprosthetic collections ex-
tended from the neck of the femoral component in to the
surrounding soft tissues, most commonly the gluteal muscles.
These collections are typically isointense to muscle on T1W
images. On T2W images, the fluid is usually hyperintense
(rarely iso- or hypointense) and enclosed by a thick irregular
pseudocapsule, which is isointense on T1W and very low
signal intensity on T2W, and sometimes referred to as syno-
vitis by other authors [20]. This very low signal is caused by
Fig. 6. Coronal T1W MRI (a, b) in a patient with an Ultima TPS THR,
and a normal plain radiograph, demonstrating intermediate signal abnor-
malities (arrows) in the marrow of the proximal femur on T1W. Anecdotal
reports from the revision procedures suggest that the MR underestimates
the extent of the marrow disease found at surgery in patients with ARMD.
Fig. 7. Sagittal (a) and axial (b) T2W MR of an ovoid soft tissue lesion lying between the right gluteus maximus and medius muscles
demonstrating very low signal with areas of subtle blooming which turned out to be a histiocytoma containing microscopic metal particles
accounting for the signal characteristics.
HSSJ (2013) 9:247–256 251
susceptibility artefact from microscopic metal particles in the
pseudocapsule, which is only apparent on long TE sequences
[41, 47] (Fig. 5). Other MR findings included gluteal tendon
avulsion, muscle oedema and atrophy, bone marrow signal
abnormalities and periprosthetic fractures [34, 47]. The MR
reports have been largely validated by surgical findings, but if
anything the impression is that MRI tends to underestimate the
extent of the disease (Fig. 6).
This case series of MRI findings in ARMD was followed
shortly by similar experience from Oxford [13]. Their expe-
rience in 17 patients with MOM resurfacing arthroplasty
(RSA) reported what they described as solid pseudotumours.
Solid lesions were uncommon in the Norwich Ultima TPS
cohort and have been almost exclusively reported with
MOM RSA, more commonly in female patients [10, 33].
We have not systematically analysed our experience of im-
aging the Birmingham RSA as we have the other prostheses,
but suffice it to say similar patterns of solid and cystic
periprosthetic soft tissue masses are commonly identified.
Lymphoreticular spread of polyethylene particles is a well-
recognized phenomenon in MOP THR but was also first
described in a Birmingham RSA using MRI [42] and has
subsequently been identified in other implants (Fig. 7). The-
se early reports have since been replicated in other symp-
tomatic cohorts [20, 38].
Our experience with the ASR cohort was different to the
Ultima TPS. Debris and heterogenous T2 weighted signal on
MRI was a common finding within periprosthetic cystic
structures in this cohort and was in contrast to a homogenous
fluid signal of the Ultima TPS. The very severe disease seen
with the Ultima TPS was not seen with the ASR; gluteal
tendon avulsion and myositis were not features of this group
[13, 41, 46]. It was noted that iliopsoas extension of the
disease was more common in the ASR cohort, and this may
be a feature of the larger bearing (Fig. 8).
The Norwich ASR and Ultima TPS cohorts are not di-
rectly comparable. The process of case selection was differ-
ent: a cross-sectional study compared to a symptomatic case
series. The ASR patients were also imaged considerably
earlier in their postoperative course than the Ultima TPS
group, and it is now clear that the mechanism of production
Fig. 8. Axial T1W (a) and sagittal T2W (b) MR in a patient with a large bearing uncemented total ASR hip replacement. A large solid iliopsoas soft
tissue lesion is present which is isointense on T1W and hypointense on T2W. Iliopsoas ARMD appears to be more common in large bearing THRs.
Table 2 The key features of the Anderson staging system for severity
of ARMD on MRI
Grade Description Criteria
C1 Mild Less than 5 cm
maximal diameter
C2 Moderate Greater than 5 cm diameter
Muscle edema or tendon
attenuation
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of debris is different: crevice corrosion in the TPS and wear
in the ASR.
It seems clear from our work and the work of others that
the spectrum of ARMD on MRI does vary with the type of
prosthesis. It seems likely that the bearing size, composition,
method of fixation and replacement of the femoral neck may
all contribute to the severity, distribution and MRI appear-
ances of ARMD.
Grading ARMD with MRI
After the initial work of diagnosing and treating those pa-
tients who had presented with severe early disease, it be-
came apparent that there were large numbers of patients
appearing who were asymptomatic or who had mild symp-
toms with relatively minor changes of ARMD on MRI.
These patients required long-term monitoring but to do this
required a standardized method of describing the severity of
changes on MRI. The system that was subsequently devised
was based on what the surgeons felt were clinically significant
features that would persuade them to monitor conservatively,
revise electively or revise urgently. These three stages of the
disease were defined as mild, moderate and severe (grades C1
to C3) (Table 2). To test the reproducibility of this grading
system, 73 MAR MR of THRs comprising known ARMD
admixed with normal controls (grade A) and patients with
proven infection (B) were anonymized and analyzed [31].
This grading system demonstrated substantial interobserver
agreement at our institution with kappa=0.61–0.8 between
the three observers (two experienced at reporting MAR MRI
and 1 not). Other authors have since reported lower levels of
agreement with Chang et al. reporting moderate interobserver
agreement, kappa=0.44 [4, 9].
This grading system is by no means universally accept-
ed. The units at Oxford and Imperial College, London have
both described their own scoring methods which are based
on MR signal characteristics which the Oxford group have
reported correlates with symptoms in that those patients with
solid lesions are more likely to experience pain [19]. This is
a fundamentally different approach to the Norwich grading
system which stages the severity of the disease in much the
same way as a local staging of a cancer would be performed.
Correlation of MRI with Clinical Symptoms
In the Norwich cohort of ASR patients, 27 (34%) of the 75
imaged hips showed MRI features of ARMD. The prevalence
of disease on MARS MRI in asymptomatic patients has been
reported by other groups in a range of 4% to 68% with the
highest prevalence in THR and the lowest in RSA [6, 17, 18,
29, 32, 44] [25]. When the grade of disease on MR, or simply
the presence or absence of ARMD, was compared with clin-
ical symptom scores, there was no statistically significant
correlation in the Norwich ASR cohort. The mean Oxford
hip score (OHS) for patients with a normal MRI was 23
(original OHS, with “best” 12 and “worst” 48) and 19 in those
with MR findings of ARMD. Severe ARMD was also ob-
served in asymptomatic patients with OHS of 12 [46]. These
findings, which suggest that clinical scores cannot be used as a
reliable tool for diagnosing or monitoring ARMD, have since
been replicated by other groups [9]. Other groups have taken a
different approach to staging AMRD by using continuous
measures of disease, rather than ordinal data, and have dem-
onstrated that there is an association between synovial volume,
and maximal synovial thickness, with the severity of ALVAL
graded histologically [31] as well as a correlation between the
severity of synovitis and symptoms in the presence of adverse
local tissue reaction [32].
Correlation of MRI with Metal Ion Levels
In response to the concern over the increasing numbers of
revisions for ARMD, the UKMedicines and Healthcare Prod-
ucts Regulatory Agency (MHRA) released a Medical Device
Alert in April 2010 [37]. These recommendations included
regular clinical follow-up of patients and investigation of those
Fig. 9. Graphs comparing the frequency distribution of serum Co (a)
and Cr (b) ions in patients with ASRTHRs with and without ARMD. The
patterns of distribution demonstrate no clinically useful correlation.
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patients with painful MOM arthroplasties with regular mea-
surement of serum Co and Cr ion levels. Radiological follow-
up was particularly recommended for those patients with
serum metal ion levels above 7 ppb (in micrograms per litre).
In an attempt to assess whether or not serum metal ion
levels are useful in monitoring ARMD, a retrospective cohort
study of all patients who had received ASR implants and who
had not undergone revisions were reviewed. Sixty-two hip
replacements in 57 patients were included in the study [27].
There were significant statistical associations between elevat-
ed serummetal ions and acetabular inclination greater than 50°
(no association with acetabular version), larger heads, female
gender (although head size may be a confounding influence),
THR rather than resurfacings and bilateral implants.
Although there was a linear correlation between serum
metal ions and the severity of disease on MRI, the sensitivity
and specificity of serum metal ions for predicting ARMD on
MRI was limited. This result has been supported by other
studies from the UK [28, 29]. The sensitivity of serum Cr
and Co was 56% for both and the specificity was 83% and
76%, respectively. Reducing the serum level to 4 μg/L in-
creased sensitivity to 61% and 66%, respectively, but at the
cost of a drop in specificity. Between 20% and 25% of patients
with serum CoCr<7 μg/L have evidence of ARMD on MR,
and all of these were asymptomatic [27] (Fig. 9). The conclu-
sion of this study is that serummetal ion measurements are not
on their own sufficiently accurate for monitoring the presence
of ARMD in asymptomatic patients.
Prognosis
Several questions arose from the MHRAMedical Device Alert
and the recommendation for routine imaging of all patients with
MOM THR. The minimal frequency of MR imaging required
to adequately screen populations of relatively asymptomatic
patients with MOM THR was not known because the natural
history of the disease was not understood.
To assess this, a retrospective study of all patients who had
undergone MAR MRI of their MOM THR on at least two
separate occasions were reviewed and every MR re-reported
and staged according to the Anderson criteria [12]. Eighty
patients with 103 THRs who had a total of 239 MRIs were
included in the study. All 80 patients had had two MR exam-
inations, 29 had had three, and four had had four serial MRIs.
The range of time from operation to MRI was 0.8 to 13.4 years
(mean 7 SD 2.4 years). For those patients whose first MRI was
classified as stage A or “normal postoperative appearances”,
9.5% developed ARMD. This occurred at 7 to 11 years after
the initial operation. For those patients with ARMD of any
grade, on any MR, 15% deteriorated on a subsequent MR.
Nineteen percent of patients staged C1 were reclassified as
normal on a subsequent MR at 5 to 7 years. This either reflects
a reduced specificity for MR in detecting mild ARMD or true
resolution of the disease (Fig. 10).
This study did not include a substantial number of pa-
tients in whom their MOM THR failed and were revised
early, and so the conclusion is that for this cohort, ARMD
appears to develop in the early post-operative phase. Those
patients with severe disease present early on. Those with
mild disease are often stable for many years, and only a
small proportion of those with normal MRIs will develop
ARMD but when they do it is usually 7 to 10 years after the
operation. In light of this, annual assessment of asymptom-
atic patients with MOM THR with MAR MRI, as recom-
mended by the MHRA, would seem to be an adequate
frequency for screening, but our evidence does not neces-
sarily apply to all types of prostheses.
Conclusion
ARMD is often a silent complication of MOM THR. Metal
artefact reduction MRI allows adequate visualization of the
periprosthetic soft tissues on most standard clinical MR sys-
tems. MR characteristics are now well described and appear to
vary from prosthesis to prosthesis. There are different ap-
proaches to the grading of the severity of ARMD on MRI;
however, there does not appear to be any good correlation
between the severity of changes at MRI and either clinical
Fig. 10. Scatterplot of grades of severity of ARMD measured with serial MRI in patients in which the first MR was normal. The plot
demonstrates that most subsequent MRI is also normal but in the 10% that develop ARMD do so between 7 and 11 years after surgery.
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symptoms scores or metal ion levels. Therefore, MRI appears
to be the most useful tool for diagnosing and monitoring
ARMD at this moment in time. Although severe early ARMD
is associated with significant morbidity, mild disease is often
stable for years. Depending on the type of prosthesis, a patient
with a normal post-operative MRI may have a 10% chance of
developing ARMD and if they do it seems to occur 7 to
11 years after surgery. A 1-year interval between MRI exam-
inations is reasonable in asymptomatic patients.
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